Intas Pharmaceuticals, has recently declared that, they began to sell Mabtas, biosimilar rituximab in the Indian market.
The company’s subsidary Intas Bio-Pharma was already selling some biosimilars, including G-CSF, Pegylated G-CSF and also erythropoietin with their own brands. Now, with a recent update, they declared that, a biosimilar version of Roche/Genentech’s Rituxan/Mabthera is being marketed in India.
“With a view to make Non-Hodgkin’s Lymphoma (NHL) treatment cost-effective, Intas Pharmaceuticals Limited has successfully launched “Mabtas” in India.
Mabtas is a biosimilar version of rituximab, competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. Such diseases include many forms of lymphoma, leukemia, and transplant rejection, autoimmune disorders such as Rheumatoid Arthritis, Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis.
Mabtas may be used alone or in combination with other chemotherapy medicines to treat Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).” the company said in their news update.
We have to note once again that, this product is not developed in accordance with global biosimilar guidelines and like Reditux, which was developed by Dr.Reddy’s, it is launched in India first.
Source: Intas Pharmaceuticals